SOLICITATION NOTICE
A -- Measurement of the Biomarkers of Immune Function and a Cytokine Panel in 500 Samples to be Collected in the Follow up Anniston Study (ACHS II)
- Notice Date
- 7/30/2013
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2013-Q-15983
- Archive Date
- 8/29/2013
- Point of Contact
- Liubov A. Kriel, Phone: 7704882856
- E-Mail Address
-
vyh1@cdc.gov
(vyh1@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Center for Disease Control and Prevention (CDC), Agency for Toxic Substances and Disease Registry (ATSDR), intends to award a sole source purchase order to the Research Foundation of State University of New York, DBA: Research Foundation of SUNY on behalf of SUNY Upstate Medical University Laboratory (SUMU), 750 E Adams St., Syracuse, NY 13210-0000 for the measurement of the biomarkers of immune function and a cytokine panel in 500 samples to be collected in the follow up Anniston study (ACHS II). The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology). The purpose of this acquisition is to perform the measurement of the biomarkers of immune function and a cytokine panel in 500 samples to be collected in the follow up Anniston study (ACHS II). SUMU Laboratory at the Department of Pharmacology and Immunology and the Microarray Core Facility and Center for Neuropsychiatric Genetics have been leading laboratories in investigation of the effects of dioxins and related compounds on immune function and effects on the Aryl-hydrocarbon receptor, as well as in the use of multiplex assay and microarray technologies in research of human cytokine and interleukine panels to characterize the modulation of immune function by environmental toxicants. Their research focuses on autoimmune disease and investigation of pro-inflammatory cytokines, interleukines and other immune parameters. The Bio-Plex Precision Pro magnetic human cytokine immunoassay panel, which will be used by SUMU for this project, contains highly sensitive, highly reproductive, magnetic bead-based assays which allow accurate measurement of low levels of human cytokines. These assays feature both low intra- and inter-assay % coefficients of variation (CV), resulting in highly precise measurements. The SUMU's intra-assay CV is <10% for all targets and below 6% for over 50% of targets. Inter-assay CV is <15% determined from 5 separate experiments. Adding a known amount of protein to plasma standard diluent at each of the indicated concentrations (111 pg/ml, 9.3 pg/ml, and 2.3 pg/ml) results in assay accuracy in the 80 -120% range, with most measurements close to 100% indicating the high consistence of results. Similarly, very low cross-reactivity (<= 1%) and high dynamic range at high PMT (1-2,500 pg/ml) complement the assays high performance parameters. In addition, the assay reports very low limits of detection for all targets in the range of 0.10 to 1.88 pg/ml. SUMU is the only laboratory that provides continuity and direct compatibility of the results for rheumatoid factor and ANA-screen/titer assays, having analyzed over 250 samples from previous study. This eliminates inter-laboratory differences to these auto-immune parameters and thus fulfills the requirement of the follow up study. Additionally, continuity is vital to accurate analysis when running the established method. Based on the above, SUMU is the only organization that can provide the services to meet all of the CDC's requirements. They are using techniques with highest sensitivity and precision for detecting custom-selected biomarkers and specifically for detection of human cytokine panels and biomarkers of immune function. In addition, the laboratory has the unique capability to perform immune assays on multiple platforms, eliminating the need to use other laboratories for different assays. It is also the only laboratory with expertise in contextualizing the results with exposure to PCBs and dioxin like compounds working through Ah-R receptors, which is necessary in the ACHS II study. Therefore, SUMU is the only company that can be used. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to Research Foundation of State University of New York. However, firms that believe they can meet these requirements are encouraged to identify themselves and give written notice by providing a capability statement to the Contracting Officer by August 14, 2013. The Contracting Specialist will not respond to verbal request. All requests must be in writing. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall be sent to Liubov Kriel by email at vyh1@cdc.gov and reference solicitation number 2013-Q-15983 on the subject line.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2013-Q-15983/listing.html)
- Place of Performance
- Address: Contractor's facility, Syracuse, New York, 13210, United States
- Zip Code: 13210
- Zip Code: 13210
- Record
- SN03131367-W 20130801/130730235619-7fce96e6ae546f1d5c527f2c20035a13 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |